Austausch für VIDAC WKN: A3DTUQ ISIN: GB00BM9XQ619 Forum: Aktien User: speculator
War einfach zu finden: Beyond the needle: Building the future of intratumoral oncology – Basel Beyond the needle: Building the future of intratumoral oncology – Basel Intratumoral oncology is emerging as a powerful complement to systemic therapies in cancer care. By delivering treatment directly into tumors, these approaches enable precise, localized activity where disease is concentrated, strengthen local control, and open new opportunities for combination with radiation, chemotherapy, and immunotherapy. Advances in this space include local immune activators, oncolytic viruses, radio-enhancers/radiosensitizers, and locally delivered cell therapies. Join Johnson & Johnson’s Interventional Oncology (INTO) and Oncology teams on October 23 in Basel for an engaging dialogue with senior leaders and experts to explore how intratumoral therapies are shaping the future of oncology. The discussion during the event will focus on key topics including: J&J’s external innovation model and how it drives partnering Interventional Oncology and Oncology strategies and sourcing priorities Partnership opportunities to advance intratumoral and systemic therapies into and through the clinic Networking with entrepreneurs, start-ups, biotech leaders, and investors During this event, organized in collaboration with BaseLaunch, you will also learn how Johnson & Johnson integrates Innovative Medicine and MedTech expertise to develop therapies designed to augment the mainstays of cancer care with complementary and synergistic locally acting drugs. 1:1 Meetings Innovators in this space are invited to apply for a 1:1 meeting with the J&J team by October 7. Discussions may cover potential collaboration, incubation, or investment opportunities across J&J Oncology’s priority disease areas, platforms, and enabling technologies. Apply Now Program 16:00 Registration 16:30 Welcome Kai Stoeber, Senior Director External Innovation, Interventional Oncology,, Johnson & Johnson Martyna Wroblewska, Manager Innovation and Sourcing BaseLaunch, BaseLaunch 16:35 Overview of J&J in Switzerland & the J&J External Innovation model Michael Hübner, Director for Early Innovation Partnering Switzerland, 16:50 Oncology at J&J: Priority disease areas Sonal Patel, VP Oncology External Innovation, Johnson & Johnson 17:00 J&J Interventional Oncology: Strategy and sourcing priorities Stewart Bates, Senior Director Discovery & Transactions INTO, Johnson & Johnson 17:15 Q&A 17:25 Panel discussion - Beyond the needle: Building the future of intratumoral oncology Moderator: Kai Stoeber, Senior Director External Innovation INTO, Johnson & Johnson Panelist: Stewart Bates, Head of Discovery & Translational Sciences, Interventional Oncology, Johnson & Johnson Panelist: Prof. Magdalena Król*, Co-founder and Chief Scientific Officer, Cellis AG Panelist: Fabio Rosa*, Co-founder & Head of Research, Asgard Therapeutics *Speaker has been invited 18:00 Q&A with panel 18:15 Networking reception Partners Johnson & Johnson Oct 23 2025
|
|
Thema | ||
|---|---|---|---|
| 1 | Beyond Meat Hauptdiskussion | +61,68 % | |
| 2 | ROCK TECH LITHIUM Hauptdiskussion | -0,33 % | |
| 3 | Hexagon Purus | -0,37 % | |
| 4 | CoinBase (Future ExChange) | +1,89 % | |
| 5 | TUI Hauptforum | -0,86 % | |
| 6 | ENPHASE ENERGY Hauptdiskussion | +4,68 % | |
| 7 | JINKOSOLAR Hauptdiskussion | +1,76 % | |
| 8 | ATLASSIAN | +6,89 % | |
| 9 | Gorilla | +9,82 % | |
| 10 | TESLA MOTORS Hauptdiskussion | -2,00 % | Alle Diskussionen |
|
|
Thema | ||
|---|---|---|---|
| 1 | Beyond Meat Hauptdiskussion | +61,68 % | |
| 2 | ROCK TECH LITHIUM Hauptdiskussion | -0,33 % | |
| 3 | Hexagon Purus | -0,37 % | |
| 4 | CoinBase (Future ExChange) | +1,89 % | |
| 5 | TUI Hauptforum | -0,86 % | |
| 6 | ENPHASE ENERGY Hauptdiskussion | +4,68 % | |
| 7 | JINKOSOLAR Hauptdiskussion | +1,76 % | |
| 8 | ATLASSIAN | +6,89 % | |
| 9 | Gorilla | +9,82 % | |
| 10 | TESLA MOTORS Hauptdiskussion | -2,00 % | Alle Diskussionen |